Stock Expert AI

Content generated by AI editorial engine. Editorially supervised by Sedat ANAK.

CRH plc
CRH - NYSE - $100.60 ▲ +%0.12
-
Earnings Wed 4 Nov

CRH opens the
books on Wednesday evening.

3 analysts' median target is $132[FMP target], stock is $101, +31.2% vs the analyst consensus median. After Q2 +9.4% EPS beat[FMP earnings], the stock moved -1.0%.

summary below
Quick Take - in 40 seconds
B+
BUY Council 4/6 - Moonshot 41

B+ = MoonshotScore 41[multi-pillar formula] + Council 4/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Quick Answer

CRH plc (CRH) Q2 consensus: revenue $11.6B[FMP est], EPS $2.30[FMP est]. 1 consecutive quarters of beat[FMP earnings].

$2.30 EPS Estimate Last year $2.21 - +3% YoY YoY
1 Beat Streak Expectations beaten consecutively for the last 1 quarters

Q2 EPS +9.4% beat[FMP] but the stock -1.0% D+1[FMP D+1].

Watchlist

6 metrics stand out this quarter.

2026 Expectation / Guide

Fy26 Ebitda Guidance

fy26_ebitda_guidance

CRH reaffirmed its adjusted EBITDA guidance for 2026 to be between $8.1 billion and $8.5 billion, despite current geopolitical and macroeconomic uncertainties.

"Notwithstanding the current geopolitical and macroeconomic uncertainties, we are pleased to reaffirm our adjusted EBITDA guidance range for 2026, representing another strong year of growth and value creation for CRH. ... we expect full year adjusted EBITDA to be between $8.1 billion and $8.5 billion, net income between $3.9 billion and $4.1 billion and diluted earnings per share between $5.60 and $6.05, representing another strong year of growth and value creation for CRH."

- Jim Mintern, CEO - Q2 FY26 Earnings Call - July 30, 2026
$10.8 billion Investor Focus

Q2 Financial Performance

q2_financial_performance

CRH delivered a robust performance in Q2 with a 6% revenue increase and a 7% adjusted EBITDA growth, achieving 30 basis points of margin expansion despite a challenging inflationary environment.

"Total revenues of $10.8 billion were 6% ahead. This translated into adjusted EBITDA of over $2.6 billion in the quarter, a 7% increase over the prior year. Despite contending with an inflationary cost environment, I am pleased to report a further 30 basis points of margin expansion, demonstrating our relentless focus on commercial excellence and strong cost discipline across our business."

- Jim Mintern, CEO - Q2 FY26 Earnings Call - July 30, 2026
$150 Investor Focus

Arcosa Acquisition

arcosa_acquisition

CRH announced an agreement to acquire Arcosa for an enterprise value of approximately $8.5 billion, which will reinforce its position as a leading infrastructure player in North America and add 35 million tonnes of annual high-quality aggregates production.

"We also recently announced an agreement to acquire Arcosa, a leading provider of building materials and critical infrastructure products in the United States. This is a significant investment, which will reinforce CRH as the leading aggregates and critical infrastructure player in North America, and I will take you through that in further detail later in the presentation. ... in June, we also reached an agreement to acquire Arcosa for a cash consideration of $150 per share, reflecting a total enterprise value of approximately $8.5 billion. ... with 35 million tonnes of annual high-quality aggregates, it will reinforce our position as the leader in U.S. aggregates with over 265 million tonnes of combined annualized production."

- Jim Mintern, CEO - Q2 FY26 Earnings Call - July 30, 2026
$1.4 billion Investor Focus

Capital Allocation Strategy

capital_allocation_strategy

CRH has invested $1.4 billion in 17 acquisitions year-to-date and sees a strong M&A pipeline, planning to allocate approximately 70% of its financial capacity to future growth investments.

"year-to-date, we've invested $1.4 billion on 17 value-accretive acquisitions across our connected growth platforms. ... Looking ahead and notwithstanding what has been an active year so far, we have a strong pipeline of further M&A opportunities in front of us, supported by our unmatched scale, connected portfolio and fragmented nature of our industry. ... over the next 5 years, we expect to have at our disposal financial capacity of approximately $40 billion. We expect to allocate approximately 70% of this to growth investments with the remaining 30% returned to shareholders through dividends and share buybacks."

- Aylwyn Bryan, CFO - Q2 FY26 Earnings Call - July 30, 2026
8 Investor Focus

Americas Building Solutions Challenges

americas_building_solutions_challenges

The Americas Building Solutions segment experienced a decline in Q2 revenues and EBITDA due to divestitures, a subdued new build residential market, and elevated haulage rates.

"Next to Americas Building Solutions on Slide 8, where our second quarter performance reflects the impact of recently completed divestitures and a subdued new build residential market. We also experienced an inflationary cost backdrop, particularly in relation to elevated haulage rates in the quarter, and we've implemented operational and commercial initiatives to mitigate these costs. ... For Americas Building Solutions overall, total revenues and adjusted EBITDA were 2% and 8% behind prior year."

- Randy Lake, COO - Q2 FY26 Earnings Call - July 30, 2026
15 Investor Focus

Arcosa Synergies

arcosa_synergies

The Arcosa acquisition is expected to generate approximately $175 million in run-rate cost synergies by year 3, with $60 million anticipated in the first year of ownership.

"And as you can see on Slide 15, we currently expect approximately $175 million of run-rate cost synergies to be achieved by year 3 with $60 million anticipated in the first year of ownership."

- Randy Lake, COO - Q2 FY26 Earnings Call - July 30, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 4 / 6 Bullish

6 investor frameworks. 4 bullish (Ray Dalio, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +31.2%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 48
Klarman value - target upside +31.2%
Buffett quality - ROE score 5/5
Munger valuation - target upside +31.2%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
48.2 RSI 48.2 balanced, 50d below
MACD
-3.70 price below 50d - resistance dominant
50d MA
$104 stock 3.7% below - short-term resistance
200d MA
$113 stock 11.3% below - long-term pressure
Volume (10d)
-34% decrease - low participation
Resistance
$132
Analyst median target - upgrade trigger if broken
Current
$101
Pre-earnings position
Support
$96
Invalidation - close below this is a technical breakdown
Pattern
Range
$96-$132 band - earnings breakout/breakdown trigger

Past Performance

CRH's last 8 quarters: 1 consecutive beats.

BEAT
Q3 FY25
$2.23 vs $2.20 est - -0.8%
MISS
Q4 FY25
$1.52 vs $1.52 est - +0.6%
MISS
Q1 FY26
$-0.27 vs $-0.22 est - -2.5%
BEAT
Q2 FY26
$2.21 vs $2.02 est - -1.0%

Q2 (July 30, 2026): EPS $2.21 vs $2.02 est[FMP], +9.4% beat. D+1 movement: -1.0%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $2.23 (no guidance)

Q2: EPS $2.21 vs $2.02 beat[FMP], stock -1.0% D+1[FMP]. Aylwyn Bryan Q2 transcript: "Notwithstanding the current geopolitical and macroeconomic uncertainties, we are pleased to reaffirm our adjusted EBITDA guidance range for 2026, representing another strong year of growth and value creation for CRH. ... we expect full year adjusted EBITDA to be between $8.1 billion and $8.5 billion, net income between $3.9 billion and $4.1 billion and diluted earnings per share between $5.60 and $6.05, representing another strong year of growth and value creation for CRH."[Aylwyn Bryan].

"Notwithstanding the current geopolitical and macroeconomic uncertainties, we are pleased to reaffirm our adjusted EBITDA guidance range for 2026, representing another strong year of growth and value creation for CRH. ... we expect full year adjusted EBITDA to be between $8.1 billion and $8.5 billion, net income between $3.9 billion and $4.1 billion and diluted earnings per share between $5.60 and $6.05, representing another strong year of growth and value creation for CRH."

- Aylwyn Bryan, CFO - Q2 FY26 Earnings Call - July 30, 2026
Backlog concentration

No RPO/backlog concentration disclosed in Q2 earnings call.

CapEx shock

Q2 CapEx $639.0M[FMP cashflow]. Q2 op margin 19.3%[FMP op margin] - this level in Q2 is sensitive to CapEx revision risk.

"Through the second quarter, we've invested approximately $800 million in growth CapEx leveraging our size and scale to fully capitalize on high-returning, low-risk investment opportunities to expand capacity in high-growth markets, improve operational efficiency, increase automation and optimize our energy usage, all of which will drive long-term shareholder value."

- Aylwyn Bryan, CFO - Q2 FY26 Earnings Call - July 30, 2026
Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q2 EPS > $2.30 + CapEx discipline
Threshold: EPS > $2.30[FMP est].
Target: Break above median target $132[FMP target]; high target $165.6[FMP] upper bound.
Scenario B - In-Line
EPS approx $2.30 + CapEx < $639.0M
Threshold: EPS approx $2.30[FMP est], Q2 CapEx < $639.0M[FMP].
Target: Consolidation in the band between current $101[FMP] and median $132[FMP].
Scenario C - Miss
EPS < $2.23 or CapEx >= $639.0M
Threshold: EPS < $2.23[FMP estx0.97].
Target: Current $101 below SMA200 $113[FMP], if rejection continues, $96[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 3 analysts say?

Wall Street Consensus
$132
12-month median target price (+31.2% gap to the analyst consensus median)
19
BUY
2
HOLD
0
SELL
Risk Management
$96
Invalidation level - critical support threshold
$104 - 50-day MA (below, -3.7%)
$113 - 200-day MA (below, -11.3%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - CRH Q2 FY27
B+

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q2 EPS threshold $2.30[FMP], CapEx threshold "below $639.0M". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Nov 4, 2026EARNINGSQ2 FY27 results (after market close) + earnings call
Nov 5, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Dec 19, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Feb 4, 2027EARNINGSQ3 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the CRH earnings preview cover?

This CRH plc (CRH) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in CRH earnings?

CRH plc (CRH): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

CRH plc (CRH): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

CRH plc (CRH): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded